X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FOR46 (FG-3246) is a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload. It is being evaluated for the treatment of metastatic castration-resistant prostate cancer.
Lead Product(s): FG-3246
Therapeutic Area: Oncology Product Name: FOR46
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
FG-3019 (pamrevlumab) is a CTGF inhibitor monoclonal antibody, which is being evaluated in phase 2/3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Pamrevlumab,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: FG-3019
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders, which is investigated for the treatment of ambulatory patients with Duchenne muscular dystrophy.
Lead Product(s): Pamrevlumab,Deflazacort
Therapeutic Area: Genetic Disease Product Name: FG-3019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders, which is investigated for the treatment of Idiopathic Pulmonary Fibrosis.
Lead Product(s): Pamrevlumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FG-3019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Lead Product(s): Pamrevlumab,Deflazacort
Therapeutic Area: Genetic Disease Product Name: FG-3019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
Evrenzo (roxadustat) is an oral medication, comprised of HIF-PH inhibitors that promote erythropoiesis, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin.
Lead Product(s): Roxadustat
Therapeutic Area: Hematology Product Name: Evrenzo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
The collaboration expands FibroGen’s clinical pipeline with potential first-in-class product candidate, FOR46, a potential first-in-class Phase 1 ADC targeting a novel epitope on CD46, being developed for the treatment of metastatic castration-resistant prostate cancer.
Lead Product(s): FOR46
Therapeutic Area: Oncology Product Name: FOR46
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Fortis Therapeutics
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 08, 2023
Details:
Evrenzo (roxadustat) is an oral medication, comprising HIF-PH inhibitors that promote erythropoiesis, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin.
Lead Product(s): Roxadustat
Therapeutic Area: Hematology Product Name: Evrenzo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
The financing will be used to advance FG-3019 (pamrevlumab), an anti-CTGF human mAb in clinical development for the treatment of IPF, LAPC, metastatic pancreatic cancer, and DMD, toward commercialization and for the development of company's pre-clinical pipeline.
Lead Product(s): Pamrevlumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FG-3019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley Tactical Value
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 01, 2023
Details:
FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Lead Product(s): Pamrevlumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FG-3019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
